{"outcome_uid": "f7f7874e", "clinical_question": "What is the diagnostic and prognostic benefit and safety of kidney biopsy among people with CKD?", "population": "Adults and/or children with suspected or diagnosed CKD", "intervention": "Native kidney biopsy", "comparator": "Clinical or standard diagnosis or prognosis for studies evaluating diagnostic or prognostic benefit; No comparator for studies evaluating safety", "outcome": "Mortality", "importance": "CRITICAL", "related_paper_list": ["a360b8c6", "523d69a3", "8d5a20a0", "c7aa8e7f", "ad427f42", "22043db1", "6cfd2bda", "27ae1de8", "f818f8cc", "080f6717", "538c0dbe", "6f44dc44", "8a3593e1", "6be4f66c", "cceb22bf"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Studies had moderate risk of bias due to concerns with potential confounding."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "There were 3 events."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"Kidney biopsy": "3/11,180 (0.0%)"}, "Effect": {"Pooled Rate (95% CI)": ["0% (0.00% to 0.00%)"]}}}, "PICO_IDX": "a1", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "9a8eaa12", "clinical_question": "What is the diagnostic and prognostic benefit and safety of kidney biopsy among people with CKD?", "population": "Adults and/or children with suspected or diagnosed CKD", "intervention": "Native kidney biopsy", "comparator": "Clinical or standard diagnosis or prognosis for studies evaluating diagnostic or prognostic benefit; No comparator for studies evaluating safety", "outcome": "Perirenal hematoma", "importance": "CRITICAL", "related_paper_list": ["8d5a20a0", "c7aa8e7f", "ad427f42", "6cfd2bda", "f818f8cc", "6f44dc44", "cceb22bf", "e2b523cc", "a99b99cf", "4be7279c", "505aba5a", "ff2b3c1e", "18733b36", "f9f9bf8d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "Studies had moderate risk of bias due to concerns with potential confounding."}, "Inconsistency": {"result": "SERIOUS", "rationales": "I2 >50%, suggesting some statistical heterogeneity."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "LOW", "No of participants": {"Kidney biopsy": "647/2943 (22.0%)"}, "Effect": {"Pooled Rate (95% CI)": ["16% (12% to 22%)"]}}}, "PICO_IDX": "a1", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "b1d15241", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "Measurement bias (eGFR - mGFR) for cystatin C-based equations", "importance": "CRITICAL", "related_paper_list": ["7e0f3ddf", "53e1d907", "f377f357", "c42a9bf3", "2a170e8f", "0ddc5c6f", "ec353ce6", "1f4862b1", "41b4fbb2", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015", "478f7225", "5afaeb79", "92bb05c1", "30dddf3d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Measurement bias is consistent across most studies with enough exceptions to cause some concern."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide range in confidence intervals (positive to negative) "}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "11602"}, "Effect": {"Range of measurement bias": ["-12.9 to 5-"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "792fe543", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "Measurement bias (eGFR - mGFR) for creatinine + cystatin-based equations", "importance": "CRITICAL", "related_paper_list": ["7e0f3ddf", "53e1d907", "c42a9bf3", "2a170e8f", "ec353ce6", "1f4862b1", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015", "478f7225", "5afaeb79", "92bb05c1"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Measurement bias is inconsistent enough across all studies to cause serious concerns."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Wide range in confidence intervals (positive to negative) "}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "13296"}, "Effect": {"Range of measurement bias": ["-9.7 to 4.1-"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "f60ad80e", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "Measurement bias (eGFR - mGFR) for creatinine-based equations", "importance": "CRITICAL", "related_paper_list": ["53e1d907", "f377f357", "c42a9bf3", "2a170e8f", "0ddc5c6f", "ec353ce6", "1f4862b1", "41b4fbb2", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015", "5afaeb79", "30dddf3d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Measurement bias is inconsistent enough across all studies to cause serious concerns."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very wide range of confidence intervals (positive to negative) spanning 20+ points."}, "Other considerations": {"result": "None", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "12491"}, "Effect": {"Range of measurement bias": ["-8.8 to 11.3-"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "79612e74", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "P30 for cystatin C-based equations", "importance": "CRITICAL", "related_paper_list": ["7e0f3ddf", "53e1d907", "c42a9bf3", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015", "478f7225", "5afaeb79", "92bb05c1", "30dddf3d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Wide range of P30 values."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very wide range of confidence intervals."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "11462"}, "Effect": {"Range of P30 Certainty": ["-59.9 to 97.8"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "d04279f6", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "P30 for creatinine + cystatin C-based equations", "importance": "CRITICAL", "related_paper_list": ["7e0f3ddf", "53e1d907", "c42a9bf3", "2a170e8f", "ec353ce6", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015", "478f7225", "5afaeb79", "30dddf3d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "Wide range of P30 values."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Wide range of confidence intervals."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "12499"}, "Effect": {"Range of P30 Certainty": ["77 to 97.6-"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "ceeaee7a", "clinical_question": "What is the diagnostic accuracy of Estimated GFR (eGFR) based on measurements of cystatin C, creatinine, or their combination compared to mGFR among people with and without CKD?", "population": "Adults and/or children with or without CKD", "intervention": "Estimated GFR (eGFR) based on measurements of cystatin C (eGFRcys); creatinine (eGFRcr); cystatin C and creatinine (eGFRcr-cys)", "comparator": "Measured GFR (mGFR; using urinary or plasma clearance of exogenous filtration marker)", "outcome": "P30 for creatinine-based equations", "importance": "CRITICAL", "related_paper_list": ["53e1d907", "f377f357", "c42a9bf3", "2a170e8f", "0ddc5c6f", "ec353ce6", "1f4862b1", "41b4fbb2", "6f773fdf", "d7ad48c0", "846571ff", "dbf9d421", "e7bfa3bd", "6fbf95e6", "401a3015"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "VERY_SERIOUS", "rationales": "Wide range of P30 values."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "Very wide range of confidence intervals."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Other Observational Study", "Certainty": "VERY LOW", "No of participants": {"eGFR-estimating equation": "12125"}, "Effect": {"Range of P30 Certainty": ["-55.5 to 96"]}}}, "PICO_IDX": "a2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "1996c990", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Progression of CKD to kidney failure* (follow-up: range 3 months to 12 months)", "importance": "CRITICAL", "related_paper_list": ["fe64e910", "952f807d"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "One of the included trials had a high risk of bias."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There was a total of 15 events among the 285 participants enrolled in the two trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ULT": "5/215 (2.3%)", "Placebo or usual care": "10/70 (14.3%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.23 (0.06 to 0.88)()", "Absolute Effect (95% CI)": "110 fewer per 1,000 (from 134 fewer to 17 fewer)()"}}}, "PICO_IDX": "b2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "e0b179ef", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Cutaneous reactions and hypersensitivity (follow-up: mean 3 months)", "importance": "CRITICAL", "related_paper_list": ["fe64e910", "d648e2a1"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "I-squared was greater than 50%."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "There was a total of 2 events among the 234 participants enrolled in the two trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ULT": "1/176 (0.6%)", "Placebo or usual care": "1/58 (1.7%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.46 (0.02 to 12.16)()", "Absolute Effect (95% CI)": "9 fewer per 1,000 (from 17 fewer to 192 more)()"}}}, "PICO_IDX": "b2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "ae76a732", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, topiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Hepatotoxicity (follow-up: range 3 months to 12 months)", "importance": "CRITICAL", "related_paper_list": ["952f807d", "d648e2a1", "0eea59fb"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "One of the included trials had a high risk of bias and another had some concerns with risk of bias."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "There was a total of 2 events among the 201 participants enrolled in the three trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"ULT": "2/128 (1.6%)", "Placebo or usual care": "0/73 (0.0%)"}, "Effect": {"Relative Effect (95% CI)": "RR 1.55 (0.16 to 14.51)()", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)()"}}}, "PICO_IDX": "b2", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "ec8baff3", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and hyperuricemia with subgroups for symptomatic and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, opiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Progression of CKD to kidney failure* (follow-up: range 12 months to 84 months)", "importance": "CRITICAL", "related_paper_list": ["4b195d32", "92d86942", "d0103bae", "d14dd133", "767b33a2", "b4a1553e"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There was a total of 71 events among the 1198 participants enrolled in the six trials. The number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ULT": "41/612 (6.7%)", "lacebo or usual care": "30/586 (5.1%)"}, "Effect": {"Relative Effect (95% CI)": "RR 1.38 (0.88 to 2.16)()", "Absolute Effect (95% CI)": "19 more per 1,000 (from 6 fewer to 59 more)()"}}}, "PICO_IDX": "b3", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "f55f73ca", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and hyperuricemia with subgroups for symptomatic and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, opiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Cutaneous reactions and hypersensitivity (follow - up: range 3 months to 41 months)", "importance": "CRITICAL", "related_paper_list": ["4b195d32", "92d86942", "b4a1553e", "4409bf3a", "9e5ec898", "f4261f50", "5757e468"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There was a total of 58 events among the 1610 participants enrolled in the seven trials. The number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"ULT": "30/803 (3.7%)", "lacebo or usual care": "28/807 (3.5%)"}, "Effect": {"Relative Effect (95% CI)": "RR 1.07 (0.64 to 1.77)()", "Absolute Effect (95% CI)": "2 more per 1,000 (from 12 fewer to 27 more)()"}}}, "PICO_IDX": "b3", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "9ead3f8b", "clinical_question": "What is the effect of uric acid–lowering therapy compared with placebo, usual care, or an active comparator among people with CKD and hyperuricemia in terms of mortality, progression of CKD, complications of CKD, and adverse events?", "population": "Adults and/or children with CKD and hyperuricemia with subgroups for symptomatic and asymptomatic hyperuricemia", "intervention": "Uric acid-lowering therapy (ULT; allopurinol, benzbromarone, febuxostat, oxipurinol, pegloticase, probenecid, opiroxostat, rasburicase, sulfinpyrazone, lesinurad)", "comparator": "Active comparator (e.g., another uric acid–lowering therapy), placebo, or usual care", "outcome": "Hepatotoxicity (follow-up: range 3 months to 25 months)", "importance": "CRITICAL", "related_paper_list": ["b4a1553e", "4409bf3a", "f4261f50", "5757e468", "3f0f91a7"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "VERY_SERIOUS", "rationales": "There was a total of 21 events among the 731 participants enrolled in the five trials. The number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"ULT": "7/363 (1.9%)", "lacebo or usual care": "14/368 (3.8%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.56 (0.23 to 1.34)()", "Absolute Effect (95% CI)": "17 fewer per 1,000 (from 29 fewer to 13 more)()"}}}, "PICO_IDX": "b3", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "1cf5c101", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Cardiovascular mortality (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["668a627a", "825aed74", "50ebb03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with the risk of bias of the 2 largest trials (Wolfe 2021 and Jardine 2010) because they were both post hoc subgroup analyses. \nThere were some concerns with risk of bias because one study (Goicoechea 2018) did not blind patients nor carers."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 185 events among the 7952 participants enrolled in the 3 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Aspirin": "56/3956 (1.4%)", "Placebo": "78/3996 (2.0%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.73 (0.52 to 1.03)()", "Absolute Effect (95% CI)": "5 fewer per 1,000 (from 9 fewer to 1 more)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "d8fed7ec", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Composite cardiovascular events (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["668a627a", "825aed74", "50ebb03a", "be0f6f0b", "971144ba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with 2 trials (Goicoechea 2018 and Saito 2011) because they did not blind patients nor carers.\nThere were some concerns with the risk of bias because 4 of the 5 trials were post hoc subgroup analyses."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"Aspirin": "242/4800 (5.0%)", "Placebo": "305/4767 (6.4%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.79 (0.62 to 1.00)()", "Absolute Effect (95% CI)": "13 fewer per 1,000 (from 24 fewer to 0 fewer)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "5ebb9179", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Myocardial infarction (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["668a627a", "825aed74", "50ebb03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with the risk of bias of the 2 largest trials (Wolfe 2021 and Jardine 2010) because they were both post hoc subgroup analyses. "}, "Inconsistency": {"result": "SERIOUS", "rationales": "I2 from meta-analysis was greater than 50%, suggesting some heterogeneity in results. There was a wide range of effect estimates."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 205 events among the 7952 participants enrolled in the 3 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Aspirin": "88/3956 (2.2%)", "Placebo": "117/3996 (2.9%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.73 (0.43 to 1.22)()", "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 17 fewer to 6 more)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "f6aa9a76", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Stroke (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["668a627a", "825aed74", "50ebb03a"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with the risk of bias of the 2 largest trials (Wolfe 2021 and Jardine 2010) because they were both post hoc subgroup analyses. \nThere were some concerns with risk of bias because one study (Goicoechea 2018) did not blind patients nor carers."}, "Inconsistency": {"result": "SERIOUS", "rationales": "I2 from meta-analysis was greater than 50%, suggesting some heterogeneity in results. There was a wide range of effect estimates."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 198 events among the 7952 participants enrolled in the 3 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Aspirin": "86/3956 (2.2%)", "Placebo": "112/3996 (2.8%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.86 (0.51 to 1.44)()", "Absolute Effect (95% CI)": "4 fewer per 1,000 (from 14 fewer to 12 more)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "edf2ae12", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Major bleeding (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["668a627a", "825aed74", "50ebb03a", "be0f6f0b", "971144ba"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with 2 trials (Goicoechea 2018 and Saito 2011) because they did not blind patients nor carers.\nThere were some concerns with the risk of bias because 4 of the 5 trials were post hoc subgroup analyses."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Not enough information is reported to assess precision."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Aspirin": "-/4800", "Placebo": "-/4767"}, "Effect": {"Relative Effect (95% CI)": "HR 1.31 (1.01 to 1.70)()", "Absolute Effect (95% CI)": "-- per 1,000 (from -- to --)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "6f61fe00", "clinical_question": "What is the effect of aspirin compared with placebo in terms of the primary prevention of cardiovascular disease (CVD) and safety among people with CKD?", "population": "Adults and/or children with CKD at risk for CVD (i.e., people must not have established CVD)", "intervention": "Aspirin", "comparator": "Placebo", "outcome": "Minor bleeding (follow-up: range 3.8 years to 5.4 years)", "importance": "CRITICAL", "related_paper_list": ["825aed74", "50ebb03a", "be0f6f0b"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were some concerns with risk of bias because 2 studies were post hoc subgroup analyses and the other study did not blind patients nor carers."}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Not enough information is reported to assess precision."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Aspirin": "-/2079", "Placebo": "-/2098"}, "Effect": {"Relative Effect (95% CI)": "HR 2.25 (1.22 to 4.14)()", "Absolute Effect (95% CI)": "-- per 1,000 (from -- to --)()"}}}, "PICO_IDX": "b4", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "b442b3a6", "clinical_question": "What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?", "population": "Adults and/or children with CKD and ischemic heart disease", "intervention": "Angiography or coronary revascularization", "comparator": "Medical treatment", "outcome": "All-cause mortality (follow-up: range 2 years to 10 years)", "importance": "CRITICAL", "related_paper_list": ["55956477", "1d2f3b00", "60f1ece6", "823b40fa"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were at least some concerns with the risk of bias for all trials. While it is not possible to blind patients/carers, not all of the trials stated that outcome assessors were blinded (Johnston 2006). Many patients needed to cross-over to the other treatment arm (Hastings 2012, Sedlis 2009), but this information was not always reported in the trials (Johnston 2006). Most of the studies were post hoc analyses of trials (Hastings 2012, Lopes 2009, Sedlis 2009). "}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 280 events among the 2243participants enrolled in the 8 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Coronary revascularization": "127/1114 (11.4%)", "Optimal medical therapy": "153/1129 (13.6%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.64 to 0.99)()", "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 49 fewer to 1 fewer)()"}}}, "PICO_IDX": "b5", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "211a52b9", "clinical_question": "What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?", "population": "Adults and/or children with CKD and ischemic heart disease", "intervention": "Angiography or coronary revascularization", "comparator": "Medical treatment", "outcome": "Cardiovascular mortality (follow-up: range 4.6 years to 5.6 years)", "importance": "CRITICAL", "related_paper_list": ["55956477", "1d2f3b00"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were at least some concerns with the risk of bias for all trials. Many patients needed to cross-over to the other treatment arm (Hastings 2012, Sedlis 2009). Most of the studies were post hoc analyses of trials (Hastings 2012, Sedlis 2009). "}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "Not enough information is reported to assess precision. The total number of events is likely to be lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "publication bias strongly suspected", "rationales": "Only 2 of the 5 trials reported on this outcome, even though all the trials assessed mortality and cardiovascular events."}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"Coronary revascularization": "-/300", "Optimal medical therapy": "-/340"}, "Effect": {"Relative Effect (95% CI)": "HR 0.67 (0.37 to 1.20)()", "Absolute Effect (95% CI)": "-- per 1,000 (from -- to --)()"}}}, "PICO_IDX": "b5", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "2d14263f", "clinical_question": "What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?", "population": "Adults and/or children with CKD and ischemic heart disease", "intervention": "Angiography or coronary revascularization", "comparator": "Medical treatment", "outcome": "Composite cardiovascular events (follow-up: range 2 years to 10 years)", "importance": "CRITICAL", "related_paper_list": ["1d2f3b00", "60f1ece6", "823b40fa", "121015f5"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were at least some concerns with the risk of bias for all trials. While it is not possible to blind patients/carers, not all of the trials stated that outcome assessors were blinded (Johnston 2006). Many patients needed to cross-over to the other treatment arm (Hastings 2012, Sedlis 2009), but this information was not always reported in the trials (Johnston 2006). Most of the studies were post hoc analyses of trials (Hastings 2012, Lopes 2009, Sedlis 2009). "}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "CI crosses 1."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Coronary revascularization": "-/965", "Optimal medical therapy": "-/958"}, "Effect": {"Relative Effect (95% CI)": "RR 0.83 (0.67 to 1.02)()", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)()"}}}, "PICO_IDX": "b5", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "8f296d07", "clinical_question": "What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?", "population": "Adults and/or children with CKD and ischemic heart disease", "intervention": "Angiography or coronary revascularization", "comparator": "Medical treatment", "outcome": "Myocardial infarction (follow-up: range 2 years to 10 years)", "importance": "CRITICAL", "related_paper_list": ["55956477", "1d2f3b00", "60f1ece6", "823b40fa", "121015f5"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were at least some concerns with the risk of bias for all trials. While it is not possible to blind patients/carers, not all of the trials stated that outcome assessors were blinded (Johnston 2006). Many patients needed to cross-over to the other treatment arm (Hastings 2012, Sedlis 2009), but this information was not always reported in the trials (Johnston 2006). Most of the studies were post hoc analyses of trials (Hastings 2012, Lopes 2009, Sedlis 2009). "}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "We cannot estimate the total number of events that occurred. There were at least 211 events among the 2243 participants enrolled in the 8 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Coronary revascularization": "-/1114", "Optimal medical therapy": "-/1129"}, "Effect": {"Relative Effect (95% CI)": "RR 0.84 (0.64 to 1.11)()", "Absolute Effect (95% CI)": "0 fewer per 1,000 (from 0 fewer to 0 fewer)()"}}}, "PICO_IDX": "b5", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "79975a9c", "clinical_question": "What are the effects of angiography or coronary revascularization compared with medical treatment among people with CKD and ischemic heart disease in terms of mortality, CVD events, kidney failure, and acute kidney injury (AKI)?", "population": "Adults and/or children with CKD and ischemic heart disease", "intervention": "Angiography or coronary revascularization", "comparator": "Medical treatment", "outcome": "Heart failure (follow-up: range 3 years to 5.6 years)", "importance": "CRITICAL", "related_paper_list": ["55956477", "1d2f3b00"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There were at least some concerns with the risk of bias for all trials. Many patients needed to cross-over to the other treatment arm (Hastings 2012, Sedlis 2009). Most of the studies were post hoc analyses of trials (Hastings 2012, Sedlis 2009). "}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 73 events among the 640 participants enrolled in the 2 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"Coronary revascularization": "30/300 (10.0%)", "Optimal medical therapy": "43/340 (12.6%)"}, "Effect": {"Relative Effect (95% CI)": "RR 0.80 (0.52 to 1.23)()", "Absolute Effect (95% CI)": "25 fewer per 1,000 (from 61 fewer to 29 more)()"}}}, "PICO_IDX": "b5", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "e777dcd1", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Any stroke (follow-up: range 1.9 years to 2.8 years)", "importance": "CRITICAL", "related_paper_list": ["c0f8d542", "bc897c67", "1cd94b34", "54a711dd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "The total number of events among the 6083 participants of the 4 trials was estimated to be less than the number needed to reach the optimal information size (i.e., 300). One study did not report the number of events (Hori 2013)."}, "Other considerations": {"result": "publication bias strongly suspected", "rationales": "Only some of the 7 studies reported on outcome."}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"NOAC": "133/3067 (4.3%)", "Warfarin": "143/3016 (4.7%)"}, "Effect": {"Relative Effect (95% CI)": "HR 0.93 (0.73 to 1.18)()", "Absolute Effect (95% CI)": "3 fewer per 1,000 (from 13 fewer to 8 more)()"}}}, "PICO_IDX": "b6", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "0e221e06", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Ischemic stroke (follow-up: range 1.8 years to 2.8 years)", "importance": "CRITICAL", "related_paper_list": ["c0f8d542", "1cd94b34", "54a711dd", "24f8f876", "e3444fca"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "The total number of events among the participants of the 5 trials was estimated to be less than the number needed to reach the optimal information size (i.e., 300). The number of events and the number of participants were not always reported."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"NOAC": "NE", "Warfarin": "NE"}, "Effect": {"Relative Effect (95% CI)": "HR 0.87 (0.69 to 1.10)()", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 1 fewer to 1 fewer)()"}}}, "PICO_IDX": "b6", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "12d65682", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Hemorrhagic stroke (follow-up: range 1.9 years to 2.8 years)", "importance": "CRITICAL", "related_paper_list": ["c0f8d542", "1cd94b34", "54a711dd"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "The total number of events among the 6083 participants of the 4 trials was estimated to be less than the number needed to reach the optimal information size (i.e., 300). One study did not report the number of events (Hori 2013)."}, "Other considerations": {"result": "publication bias strongly suspected", "rationales": "Only some of the 7 studies reported on outcome."}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"NOAC": "23/2994 (0.8%)", "Warfarin": "36/2980 (1.2%)"}, "Effect": {"Relative Effect (95% CI)": "HR 0.62 (0.36 to 1.04)()", "Absolute Effect (95% CI)": "5 fewer per 1,000 (from 8 fewer to 0 fewer)()"}}}, "PICO_IDX": "b6", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "42525beb", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Intracranial hemorrhage (follow-up: range 1.9 years to 2.8 years)", "importance": "CRITICAL", "related_paper_list": ["c0f8d542", "1cd94b34", "e3444fca"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "There were only 91 events across the 5945 participants enrolled in the 3 trials. The total number of events is lower than the number needed to reach the optimal information size (i.e., 300)."}, "Other considerations": {"result": "publication bias strongly suspected", "rationales": "Only some of the 7 studies reported on outcome."}, "Study design": "Randomized Controlled Trial", "Certainty": "LOW", "No of participants": {"NOAC": "32/2981 (1.1%)", "Warfarin": "59/2964 (2.0%)"}, "Effect": {"Relative Effect (95% CI)": "HR 0.60 (0.34 to 1.05)()", "Absolute Effect (95% CI)": "8 fewer per 1,000 (from 13 fewer to 1 more)()"}}}, "PICO_IDX": "b7", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "965eafb5", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Major bleeding (factor Xa inhibitors) (follow-up: range 6 months to 2.8 years)", "importance": "CRITICAL", "related_paper_list": ["c0f8d542", "bc897c67", "1cd94b34", "54a711dd", "e3444fca", "e152d0a8"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "SERIOUS", "rationales": "There were some concerns with the risk of bias, particularly with the reporting of selected results and the potential for missing data."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"NOAC": "NE", "Warfarin": "NE"}, "Effect": {"Relative Effect (95% CI)": "HR 0.73 (0.58 to 0.92)()", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 1 fewer to 1 fewer)()"}}}, "PICO_IDX": "b7", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "bed07c18", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Major bleeding (factor IIa inhibitors) (follow-up: median 1.8 years)", "importance": "CRITICAL", "related_paper_list": ["24f8f876"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "SERIOUS", "rationales": "There was some statistical heterogeneity in the meta-analysis results (I2 = 50%)."}, "Inconsistency": {"result": "SERIOUS", "rationales": "Only one study addressed this outcome for this comparison."}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "SERIOUS", "rationales": "The total number of events among the participants enrolled in the trial is estimated to be less than the number needed to reach the optimal information size (i.e., 300). The number of events and the number of participants were not reported."}, "Other considerations": {"result": "none", "rationales": ""}, "Study design": "Randomized Controlled Trial", "Certainty": "VERY LOW", "No of participants": {"NOAC": "NE", "Warfarin": "NE"}, "Effect": {"Relative Effect (95% CI)": "HR 1.11 (0.97 to 1.27)()", "Absolute Effect (95% CI)": "1 fewer per 1,000 (from 1 fewer to 1 fewer)()"}}}, "PICO_IDX": "b7", "Database": "2024 KDIGO CKD"}
{"outcome_uid": "dbc34756", "clinical_question": "What are the effects of non–vitamin K antagonist oral anticoagulants (NOACs) (also known as direct-acting oral anticoagulants [DOACs]) with or without warfarin compared with placebo or warfarin alone among people with CKD and atrial fibrillation in terms of stroke and bleeding risks?", "population": "Adults and/or children with CKD and atrial fibrillation", "intervention": "NOAC/DOAC (dabigatran, apixaban, edoxaban, rivaroxaban) with warfarin and NOAC/DOAC alone", "comparator": "Warfarin, placebo", "outcome": "Clinically-relevant non-major bleeding (follow-up: range 1.9 years to 2.5 years)", "importance": "CRITICAL", "related_paper_list": ["bc897c67", "1cd94b34", "54a711dd", "e3444fca"], "assessment_results": {"GRADE": {"Risk of bias": {"result": "NOT_SERIOUS", "rationales": ""}, "Inconsistency": {"result": "NOT_SERIOUS", "rationales": ""}, "Indirectness": {"result": "NOT_SERIOUS", "rationales": ""}, "Imprecision": {"result": "NOT_SERIOUS", "rationales": ""}, "Other considerations": {"result": "publication bias strongly suspected", "rationales": "Only some of the 7 studies reported on outcome."}, "Study design": "Randomized Controlled Trial", "Certainty": "MODERATE", "No of participants": {"NOAC": "346/1803 (19.2%)", "Warfarin": "334/1752 (19.1%)"}, "Effect": {"Relative Effect (95% CI)": "HR 1.06 (0.86 to 1.31)()", "Absolute Effect (95% CI)": "10 more per 1,000 (from 24 fewer to 51 more)()"}}}, "PICO_IDX": "b7", "Database": "2024 KDIGO CKD"}
